Theriva Biologics, Inc. Long-Term Debt, Maturity, Year One
Theriva Biologics, Inc. (TOVX) had Long-Term Debt, Maturity, Year One of $36.00 thousand as of 2025-06-30, per its 10-Q filed 2025-08-11.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths · last filed 2025-08-11
- 2025-06-30: Long-Term Debt, Maturity, Year One $36.00K.
- 2025-03-31: Long-Term Debt, Maturity, Year One $53.00K.
- 2024-12-31: Long-Term Debt, Maturity, Year One $61.00K.
- 2024-09-30: Long-Term Debt, Maturity, Year One $65.00K.
| Period end | Long-Term Debt, Maturity, Year One |
|---|---|
| 2025-06-30 | $36.00K 10-Q · filed 2025-08-11 |
| 2025-03-31 | $53.00K 10-Q · filed 2025-05-14 |
| 2024-12-31 | $61.00K 10-K · filed 2025-03-06 |
| 2024-09-30 | $65.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $62.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $64.00K 10-Q · filed 2024-05-07 |
| 2023-12-31 | $63.00K 10-K · filed 2024-03-25 |
| 2023-09-30 | $65.00K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $62.00K 10-Q · filed 2023-08-08 |
| 2023-03-31 | $8.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $57.00K 10-K · filed 2023-03-30 |
| 2022-09-30 | $52.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $56.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $68.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |